SlideShare a Scribd company logo
1 of 3
Download to read offline
Biochempeg https://www.biochempeg.com
FDA Approves Sacituzumab Govitecan for
Triple-Negative Breast Cancer
On April 22, 2020, the FDA has granted an accelerated approval to the
antibody-drug conjugate (ADC) sacituzumab govitecan-hziy (Trodelvy,
Immunomedics, Inc.) for the treatment of adult patients with metastatic
triple-negative breast cancer (TNBC) who have received at least 2 prior
therapies for metastatic disease. This is the first antibody conjugated
drug targeting against TROP-2 that has received FDA approval to treat
metastatic TNBC.
Image Source: https://pubs.acs.org/
Trop2 is a cell surface protein expressed in many solid tumors, which makes
Trodelvy® potentially treat a variety of cancers. Trodelvy®'s cytotoxic small
molecule drug is irinotecan's active metabolite SN-38 molecule, using
Immunomedics' unique ADC platform. Trodelvy® combines with Trop2 and
provides the anticancer drug SN-38 to kill cancer cells. Trodelvy® is currently
undergoing clinical evaluation to treat 8 refractory solid tumors.
The FDA's approval is based on the results of a single-arm clinical phase II trial
involving 108 patients with metastatic TNBC. Trodelvy demonstrated an ORR
Biochempeg https://www.biochempeg.com
of 33.3 percent (95 percent CI: 24.6, 43.1) and a median DoR of 7.7 months
(95 percent CI: 4.9, 10.8). Of the patients with a response to Trodelvy, 55.6%
maintained their response for 6 or more months and 16.7% maintained their
response for 12 or more months.
Image source: Immunomedics
About TNBC & Therapies
Breast cancer is the most common type of cancer in women, with more than 2
million cases diagnosed worldwide each year. Three-negative breast cancer
(TNBC) accounts for about 20% of all breast cancers. Compared with other
types of breast cancer, TNBC is more common in women under 50 years of
age. TNBC refers to breast cancer with negative expression of estrogen
receptor (ER), progesterone receptor (PR) and HER-2 / neu. It progresses
rapidly, with a very poor prognosis, and the 5-year survival rate is less than
15%. TNBC is ineffective for hormone therapy and HER2 targeted therapy
(such as Herceptin of Roche). Clinical treatment options are very limited and
mainly rely on chemotherapy.
Currently, there are 21 triple-negative breast cancer treatment drugs, 2 of
which are on the market and 19 are in research. The first triple-negative breast
cancer drug on the market was Roche's Atezolizumab, which was initially
marketed in the United States in 2016. In 2019, global sales reached 1.932
billion US dollars.
There are 4 types of triple-negative breast cancer drugs in clinical phase II, 5
types in clinical phase I / II, and 7 types in clinical phase I. It can be said that
Biochempeg https://www.biochempeg.com
the reserve power is sufficient, but the R & D progress is relatively slow.
Drugs Targeting Trop2
At present, there are five drugs targeting Trop2 in the world. In addition to the
listed Sacituzumab govitecan, the other four drugs under study are basically in
clinical phase I. The fastest R & D progress is SKB-264 of Kelun
Pharmaceutical, which is currently in the clinical I / II phase of solid tumor
treatment.
Related Articles:
Anti-Cancer ADC Drugs: 3 Design Elements, 8 Approved ADCs, Multiple
Clinical Trials
ADC Drugs to be Launched In 2020
ADCs for Clinical Research in the Global Market
History and Development of Antibody Drug Conjugates (ADCs)
ADCs Against Cancer: Clinical Landscape and Challenges

More Related Content

What's hot (7)

Chimeric Antigen Receptor (car) Technique-Creative Biolabs
Chimeric Antigen Receptor (car) Technique-Creative BiolabsChimeric Antigen Receptor (car) Technique-Creative Biolabs
Chimeric Antigen Receptor (car) Technique-Creative Biolabs
 
Chemotherapy
ChemotherapyChemotherapy
Chemotherapy
 
Global & usa cancer immunotherapy market analysis to 2020
Global & usa cancer immunotherapy market analysis to 2020Global & usa cancer immunotherapy market analysis to 2020
Global & usa cancer immunotherapy market analysis to 2020
 
CAR-T Cell Products Validation
CAR-T Cell Products ValidationCAR-T Cell Products Validation
CAR-T Cell Products Validation
 
Targeted cancer therapies
Targeted cancer therapiesTargeted cancer therapies
Targeted cancer therapies
 
Ra updates(xaljanz)
Ra updates(xaljanz)Ra updates(xaljanz)
Ra updates(xaljanz)
 
Major seminar1
Major seminar1Major seminar1
Major seminar1
 

Similar to Fda approves sacituzumab govitecan for triple negative breast cancer

July 2015 Cancer immunotherapy update
July 2015 Cancer immunotherapy updateJuly 2015 Cancer immunotherapy update
July 2015 Cancer immunotherapy update
Yujia Sun
 

Similar to Fda approves sacituzumab govitecan for triple negative breast cancer (20)

List of New Anti-cancer Drugs Approved By FDA In The First Half of 2023.pdf
List of New Anti-cancer Drugs Approved By FDA In The First Half of 2023.pdfList of New Anti-cancer Drugs Approved By FDA In The First Half of 2023.pdf
List of New Anti-cancer Drugs Approved By FDA In The First Half of 2023.pdf
 
Advances in triple negative breast cancer (tnbc) targeted therapy drugs
Advances in triple negative breast cancer (tnbc) targeted therapy drugsAdvances in triple negative breast cancer (tnbc) targeted therapy drugs
Advances in triple negative breast cancer (tnbc) targeted therapy drugs
 
ADC Drugs For Non-small Cell Lung Cancer.pdf
ADC Drugs For Non-small Cell Lung Cancer.pdfADC Drugs For Non-small Cell Lung Cancer.pdf
ADC Drugs For Non-small Cell Lung Cancer.pdf
 
Advances in TROP-2 Directed ADCs.pdf
Advances in TROP-2 Directed ADCs.pdfAdvances in TROP-2 Directed ADCs.pdf
Advances in TROP-2 Directed ADCs.pdf
 
Overview 120 New Therapeutic Drugs For Solid Tumors In The Past 30 Years.pdf
Overview 120 New Therapeutic Drugs For Solid Tumors In The Past 30 Years.pdfOverview 120 New Therapeutic Drugs For Solid Tumors In The Past 30 Years.pdf
Overview 120 New Therapeutic Drugs For Solid Tumors In The Past 30 Years.pdf
 
Clinical Development of ADC Drugs Targeting TROP-2.pdf
Clinical Development of ADC Drugs Targeting TROP-2.pdfClinical Development of ADC Drugs Targeting TROP-2.pdf
Clinical Development of ADC Drugs Targeting TROP-2.pdf
 
GSK's Jemperli.pdf
GSK's Jemperli.pdfGSK's Jemperli.pdf
GSK's Jemperli.pdf
 
Adc drugs to be launched in 2020
Adc drugs to be launched in 2020Adc drugs to be launched in 2020
Adc drugs to be launched in 2020
 
Antibody–Drug Conjugates for the Treatment of Breast Cancer.pdf
Antibody–Drug Conjugates for the Treatment of Breast Cancer.pdfAntibody–Drug Conjugates for the Treatment of Breast Cancer.pdf
Antibody–Drug Conjugates for the Treatment of Breast Cancer.pdf
 
Summary of Approved HER2 ADCs on The Market & in Clinical Trials.pdf
Summary of Approved HER2 ADCs on The Market & in Clinical Trials.pdfSummary of Approved HER2 ADCs on The Market & in Clinical Trials.pdf
Summary of Approved HER2 ADCs on The Market & in Clinical Trials.pdf
 
Summary of ADCs in Clinical Phase 3.pdf
Summary of ADCs in Clinical Phase 3.pdfSummary of ADCs in Clinical Phase 3.pdf
Summary of ADCs in Clinical Phase 3.pdf
 
Overview of New Targets For Anti-tumor Drugs.pdf
Overview of New Targets For Anti-tumor Drugs.pdfOverview of New Targets For Anti-tumor Drugs.pdf
Overview of New Targets For Anti-tumor Drugs.pdf
 
Kadcyla - Top-Selling Antibody Drug Conjugate (ADC).pdf
Kadcyla - Top-Selling Antibody Drug Conjugate (ADC).pdfKadcyla - Top-Selling Antibody Drug Conjugate (ADC).pdf
Kadcyla - Top-Selling Antibody Drug Conjugate (ADC).pdf
 
ADCs Targeting the HER Family.pdf
ADCs Targeting the HER Family.pdfADCs Targeting the HER Family.pdf
ADCs Targeting the HER Family.pdf
 
8. newer chemical entities for cancer treatment
8. newer chemical entities for cancer treatment8. newer chemical entities for cancer treatment
8. newer chemical entities for cancer treatment
 
A Look into Antibody–drug conjugates (ADCs) Targets.pdf
A Look into Antibody–drug conjugates (ADCs) Targets.pdfA Look into Antibody–drug conjugates (ADCs) Targets.pdf
A Look into Antibody–drug conjugates (ADCs) Targets.pdf
 
July 2015 Cancer immunotherapy update
July 2015 Cancer immunotherapy updateJuly 2015 Cancer immunotherapy update
July 2015 Cancer immunotherapy update
 
Trophoblast Glycoprotein (TPGB5T4) A New Target For ADC Drugs.pdf
Trophoblast Glycoprotein (TPGB5T4) A New Target For ADC Drugs.pdfTrophoblast Glycoprotein (TPGB5T4) A New Target For ADC Drugs.pdf
Trophoblast Glycoprotein (TPGB5T4) A New Target For ADC Drugs.pdf
 
Cancer Targetting Drug Delivery System
Cancer Targetting Drug Delivery SystemCancer Targetting Drug Delivery System
Cancer Targetting Drug Delivery System
 
Bispecific Antibody-drug Conjugate Drugs In Clinical or Preclinical.pdf
Bispecific Antibody-drug Conjugate Drugs In Clinical or Preclinical.pdfBispecific Antibody-drug Conjugate Drugs In Clinical or Preclinical.pdf
Bispecific Antibody-drug Conjugate Drugs In Clinical or Preclinical.pdf
 

More from DoriaFang

More from DoriaFang (20)

Cyclic Peptides Current Status & Future Prospects.pdf
Cyclic Peptides Current Status & Future Prospects.pdfCyclic Peptides Current Status & Future Prospects.pdf
Cyclic Peptides Current Status & Future Prospects.pdf
 
Antibody–Oligonucleotide Conjugates (AOCs) in Clinical Trials.pdf
Antibody–Oligonucleotide Conjugates (AOCs) in Clinical Trials.pdfAntibody–Oligonucleotide Conjugates (AOCs) in Clinical Trials.pdf
Antibody–Oligonucleotide Conjugates (AOCs) in Clinical Trials.pdf
 
Alzheimer's Disease Drug Development Aducanumab, Lecanemab & Donanemab.pdf
Alzheimer's Disease Drug Development Aducanumab, Lecanemab & Donanemab.pdfAlzheimer's Disease Drug Development Aducanumab, Lecanemab & Donanemab.pdf
Alzheimer's Disease Drug Development Aducanumab, Lecanemab & Donanemab.pdf
 
Claudin6 (CLDN6) A Emerging Target For Solid Tumor.pdf
Claudin6 (CLDN6) A Emerging Target For Solid Tumor.pdfClaudin6 (CLDN6) A Emerging Target For Solid Tumor.pdf
Claudin6 (CLDN6) A Emerging Target For Solid Tumor.pdf
 
ROR1 ADCs in Clinical Trials MK-2140, NBE-002 & CS5001.pdf
ROR1 ADCs in Clinical Trials MK-2140, NBE-002 & CS5001.pdfROR1 ADCs in Clinical Trials MK-2140, NBE-002 & CS5001.pdf
ROR1 ADCs in Clinical Trials MK-2140, NBE-002 & CS5001.pdf
 
Summary of Targeted Protein Degradation in Clinical Trials.pdf
Summary of Targeted Protein Degradation in Clinical Trials.pdfSummary of Targeted Protein Degradation in Clinical Trials.pdf
Summary of Targeted Protein Degradation in Clinical Trials.pdf
 
Cleavable Linkers Used In ADC Development.pdf
Cleavable Linkers Used In ADC Development.pdfCleavable Linkers Used In ADC Development.pdf
Cleavable Linkers Used In ADC Development.pdf
 
The Role of Four Lipid Components Of LNPs.pdf
The Role of Four Lipid Components Of LNPs.pdfThe Role of Four Lipid Components Of LNPs.pdf
The Role of Four Lipid Components Of LNPs.pdf
 
DS-8201 (Enhertu) A Potential ADC Drug Targeting HER2.pdf
DS-8201 (Enhertu) A Potential ADC Drug Targeting HER2.pdfDS-8201 (Enhertu) A Potential ADC Drug Targeting HER2.pdf
DS-8201 (Enhertu) A Potential ADC Drug Targeting HER2.pdf
 
Overview of Oral Delivery Strategies for Peptides.pdf
Overview of Oral Delivery Strategies for Peptides.pdfOverview of Oral Delivery Strategies for Peptides.pdf
Overview of Oral Delivery Strategies for Peptides.pdf
 
The Future Development of ADC For Cancer.pdf
The Future Development of ADC For Cancer.pdfThe Future Development of ADC For Cancer.pdf
The Future Development of ADC For Cancer.pdf
 
Summary of ADC Targets For Solid Tumors & Hematological Tumors.pdf
Summary of ADC Targets For Solid Tumors & Hematological Tumors.pdfSummary of ADC Targets For Solid Tumors & Hematological Tumors.pdf
Summary of ADC Targets For Solid Tumors & Hematological Tumors.pdf
 
New Oncology Trends ADCs, Bispecific Antibodies & CAR-T Cell.pdf
New Oncology Trends ADCs, Bispecific Antibodies & CAR-T Cell.pdfNew Oncology Trends ADCs, Bispecific Antibodies & CAR-T Cell.pdf
New Oncology Trends ADCs, Bispecific Antibodies & CAR-T Cell.pdf
 
Summary of Treatments for Multiple Myeloma.pdf
Summary of Treatments for Multiple Myeloma.pdfSummary of Treatments for Multiple Myeloma.pdf
Summary of Treatments for Multiple Myeloma.pdf
 
Nectin-4 New Antibody-Drug Conjugate (ADC) Target.pdf
Nectin-4 New Antibody-Drug Conjugate (ADC) Target.pdfNectin-4 New Antibody-Drug Conjugate (ADC) Target.pdf
Nectin-4 New Antibody-Drug Conjugate (ADC) Target.pdf
 
PROTAC Delivery System Recent Research Advances.pdf
PROTAC Delivery System Recent Research Advances.pdfPROTAC Delivery System Recent Research Advances.pdf
PROTAC Delivery System Recent Research Advances.pdf
 
Aptamer-Drug Conjugate (ApDC) Current Research Progress.pdf
Aptamer-Drug Conjugate (ApDC) Current Research Progress.pdfAptamer-Drug Conjugate (ApDC) Current Research Progress.pdf
Aptamer-Drug Conjugate (ApDC) Current Research Progress.pdf
 
Summary of Molecular Glues Approved or in Clinical Trial.pdf
Summary of Molecular Glues Approved or in Clinical Trial.pdfSummary of Molecular Glues Approved or in Clinical Trial.pdf
Summary of Molecular Glues Approved or in Clinical Trial.pdf
 
FRα Targeting ADCs for Ovarian cancer.pdf
FRα Targeting ADCs for Ovarian cancer.pdfFRα Targeting ADCs for Ovarian cancer.pdf
FRα Targeting ADCs for Ovarian cancer.pdf
 
FRα Another Hot Target In The ADC Field.pdf
FRα Another Hot Target In The ADC Field.pdfFRα Another Hot Target In The ADC Field.pdf
FRα Another Hot Target In The ADC Field.pdf
 

Recently uploaded

Call Girls in Gagan Vihar (delhi) call me [🔝 9953056974 🔝] escort service 24X7
Call Girls in Gagan Vihar (delhi) call me [🔝  9953056974 🔝] escort service 24X7Call Girls in Gagan Vihar (delhi) call me [🔝  9953056974 🔝] escort service 24X7
Call Girls in Gagan Vihar (delhi) call me [🔝 9953056974 🔝] escort service 24X7
9953056974 Low Rate Call Girls In Saket, Delhi NCR
 
Call Girls Aurangabad Just Call 8250077686 Top Class Call Girl Service Available
Call Girls Aurangabad Just Call 8250077686 Top Class Call Girl Service AvailableCall Girls Aurangabad Just Call 8250077686 Top Class Call Girl Service Available
Call Girls Aurangabad Just Call 8250077686 Top Class Call Girl Service Available
Dipal Arora
 
Call Girls Bhubaneswar Just Call 9907093804 Top Class Call Girl Service Avail...
Call Girls Bhubaneswar Just Call 9907093804 Top Class Call Girl Service Avail...Call Girls Bhubaneswar Just Call 9907093804 Top Class Call Girl Service Avail...
Call Girls Bhubaneswar Just Call 9907093804 Top Class Call Girl Service Avail...
Dipal Arora
 

Recently uploaded (20)

Best Rate (Guwahati ) Call Girls Guwahati ⟟ 8617370543 ⟟ High Class Call Girl...
Best Rate (Guwahati ) Call Girls Guwahati ⟟ 8617370543 ⟟ High Class Call Girl...Best Rate (Guwahati ) Call Girls Guwahati ⟟ 8617370543 ⟟ High Class Call Girl...
Best Rate (Guwahati ) Call Girls Guwahati ⟟ 8617370543 ⟟ High Class Call Girl...
 
Call Girls Faridabad Just Call 9907093804 Top Class Call Girl Service Available
Call Girls Faridabad Just Call 9907093804 Top Class Call Girl Service AvailableCall Girls Faridabad Just Call 9907093804 Top Class Call Girl Service Available
Call Girls Faridabad Just Call 9907093804 Top Class Call Girl Service Available
 
Russian Call Girls Service Jaipur {8445551418} ❤️PALLAVI VIP Jaipur Call Gir...
Russian Call Girls Service  Jaipur {8445551418} ❤️PALLAVI VIP Jaipur Call Gir...Russian Call Girls Service  Jaipur {8445551418} ❤️PALLAVI VIP Jaipur Call Gir...
Russian Call Girls Service Jaipur {8445551418} ❤️PALLAVI VIP Jaipur Call Gir...
 
Night 7k to 12k Chennai City Center Call Girls 👉👉 7427069034⭐⭐ 100% Genuine E...
Night 7k to 12k Chennai City Center Call Girls 👉👉 7427069034⭐⭐ 100% Genuine E...Night 7k to 12k Chennai City Center Call Girls 👉👉 7427069034⭐⭐ 100% Genuine E...
Night 7k to 12k Chennai City Center Call Girls 👉👉 7427069034⭐⭐ 100% Genuine E...
 
Call Girls Cuttack Just Call 9907093804 Top Class Call Girl Service Available
Call Girls Cuttack Just Call 9907093804 Top Class Call Girl Service AvailableCall Girls Cuttack Just Call 9907093804 Top Class Call Girl Service Available
Call Girls Cuttack Just Call 9907093804 Top Class Call Girl Service Available
 
Premium Bangalore Call Girls Jigani Dail 6378878445 Escort Service For Hot Ma...
Premium Bangalore Call Girls Jigani Dail 6378878445 Escort Service For Hot Ma...Premium Bangalore Call Girls Jigani Dail 6378878445 Escort Service For Hot Ma...
Premium Bangalore Call Girls Jigani Dail 6378878445 Escort Service For Hot Ma...
 
Call Girls Ludhiana Just Call 9907093804 Top Class Call Girl Service Available
Call Girls Ludhiana Just Call 9907093804 Top Class Call Girl Service AvailableCall Girls Ludhiana Just Call 9907093804 Top Class Call Girl Service Available
Call Girls Ludhiana Just Call 9907093804 Top Class Call Girl Service Available
 
Call Girls Jabalpur Just Call 8250077686 Top Class Call Girl Service Available
Call Girls Jabalpur Just Call 8250077686 Top Class Call Girl Service AvailableCall Girls Jabalpur Just Call 8250077686 Top Class Call Girl Service Available
Call Girls Jabalpur Just Call 8250077686 Top Class Call Girl Service Available
 
Call Girls in Gagan Vihar (delhi) call me [🔝 9953056974 🔝] escort service 24X7
Call Girls in Gagan Vihar (delhi) call me [🔝  9953056974 🔝] escort service 24X7Call Girls in Gagan Vihar (delhi) call me [🔝  9953056974 🔝] escort service 24X7
Call Girls in Gagan Vihar (delhi) call me [🔝 9953056974 🔝] escort service 24X7
 
Call Girls Nagpur Just Call 9907093804 Top Class Call Girl Service Available
Call Girls Nagpur Just Call 9907093804 Top Class Call Girl Service AvailableCall Girls Nagpur Just Call 9907093804 Top Class Call Girl Service Available
Call Girls Nagpur Just Call 9907093804 Top Class Call Girl Service Available
 
Premium Call Girls In Jaipur {8445551418} ❤️VVIP SEEMA Call Girl in Jaipur Ra...
Premium Call Girls In Jaipur {8445551418} ❤️VVIP SEEMA Call Girl in Jaipur Ra...Premium Call Girls In Jaipur {8445551418} ❤️VVIP SEEMA Call Girl in Jaipur Ra...
Premium Call Girls In Jaipur {8445551418} ❤️VVIP SEEMA Call Girl in Jaipur Ra...
 
Premium Call Girls Cottonpet Whatsapp 7001035870 Independent Escort Service
Premium Call Girls Cottonpet Whatsapp 7001035870 Independent Escort ServicePremium Call Girls Cottonpet Whatsapp 7001035870 Independent Escort Service
Premium Call Girls Cottonpet Whatsapp 7001035870 Independent Escort Service
 
Call Girls Service Jaipur {9521753030} ❤️VVIP RIDDHI Call Girl in Jaipur Raja...
Call Girls Service Jaipur {9521753030} ❤️VVIP RIDDHI Call Girl in Jaipur Raja...Call Girls Service Jaipur {9521753030} ❤️VVIP RIDDHI Call Girl in Jaipur Raja...
Call Girls Service Jaipur {9521753030} ❤️VVIP RIDDHI Call Girl in Jaipur Raja...
 
Call Girls Siliguri Just Call 8250077686 Top Class Call Girl Service Available
Call Girls Siliguri Just Call 8250077686 Top Class Call Girl Service AvailableCall Girls Siliguri Just Call 8250077686 Top Class Call Girl Service Available
Call Girls Siliguri Just Call 8250077686 Top Class Call Girl Service Available
 
Call Girls Aurangabad Just Call 8250077686 Top Class Call Girl Service Available
Call Girls Aurangabad Just Call 8250077686 Top Class Call Girl Service AvailableCall Girls Aurangabad Just Call 8250077686 Top Class Call Girl Service Available
Call Girls Aurangabad Just Call 8250077686 Top Class Call Girl Service Available
 
♛VVIP Hyderabad Call Girls Chintalkunta🖕7001035870🖕Riya Kappor Top Call Girl ...
♛VVIP Hyderabad Call Girls Chintalkunta🖕7001035870🖕Riya Kappor Top Call Girl ...♛VVIP Hyderabad Call Girls Chintalkunta🖕7001035870🖕Riya Kappor Top Call Girl ...
♛VVIP Hyderabad Call Girls Chintalkunta🖕7001035870🖕Riya Kappor Top Call Girl ...
 
Pondicherry Call Girls Book Now 9630942363 Top Class Pondicherry Escort Servi...
Pondicherry Call Girls Book Now 9630942363 Top Class Pondicherry Escort Servi...Pondicherry Call Girls Book Now 9630942363 Top Class Pondicherry Escort Servi...
Pondicherry Call Girls Book Now 9630942363 Top Class Pondicherry Escort Servi...
 
Call Girls Haridwar Just Call 8250077686 Top Class Call Girl Service Available
Call Girls Haridwar Just Call 8250077686 Top Class Call Girl Service AvailableCall Girls Haridwar Just Call 8250077686 Top Class Call Girl Service Available
Call Girls Haridwar Just Call 8250077686 Top Class Call Girl Service Available
 
Call Girls Bhubaneswar Just Call 9907093804 Top Class Call Girl Service Avail...
Call Girls Bhubaneswar Just Call 9907093804 Top Class Call Girl Service Avail...Call Girls Bhubaneswar Just Call 9907093804 Top Class Call Girl Service Avail...
Call Girls Bhubaneswar Just Call 9907093804 Top Class Call Girl Service Avail...
 
Call Girls Guntur Just Call 8250077686 Top Class Call Girl Service Available
Call Girls Guntur  Just Call 8250077686 Top Class Call Girl Service AvailableCall Girls Guntur  Just Call 8250077686 Top Class Call Girl Service Available
Call Girls Guntur Just Call 8250077686 Top Class Call Girl Service Available
 

Fda approves sacituzumab govitecan for triple negative breast cancer

  • 1. Biochempeg https://www.biochempeg.com FDA Approves Sacituzumab Govitecan for Triple-Negative Breast Cancer On April 22, 2020, the FDA has granted an accelerated approval to the antibody-drug conjugate (ADC) sacituzumab govitecan-hziy (Trodelvy, Immunomedics, Inc.) for the treatment of adult patients with metastatic triple-negative breast cancer (TNBC) who have received at least 2 prior therapies for metastatic disease. This is the first antibody conjugated drug targeting against TROP-2 that has received FDA approval to treat metastatic TNBC. Image Source: https://pubs.acs.org/ Trop2 is a cell surface protein expressed in many solid tumors, which makes Trodelvy® potentially treat a variety of cancers. Trodelvy®'s cytotoxic small molecule drug is irinotecan's active metabolite SN-38 molecule, using Immunomedics' unique ADC platform. Trodelvy® combines with Trop2 and provides the anticancer drug SN-38 to kill cancer cells. Trodelvy® is currently undergoing clinical evaluation to treat 8 refractory solid tumors. The FDA's approval is based on the results of a single-arm clinical phase II trial involving 108 patients with metastatic TNBC. Trodelvy demonstrated an ORR
  • 2. Biochempeg https://www.biochempeg.com of 33.3 percent (95 percent CI: 24.6, 43.1) and a median DoR of 7.7 months (95 percent CI: 4.9, 10.8). Of the patients with a response to Trodelvy, 55.6% maintained their response for 6 or more months and 16.7% maintained their response for 12 or more months. Image source: Immunomedics About TNBC & Therapies Breast cancer is the most common type of cancer in women, with more than 2 million cases diagnosed worldwide each year. Three-negative breast cancer (TNBC) accounts for about 20% of all breast cancers. Compared with other types of breast cancer, TNBC is more common in women under 50 years of age. TNBC refers to breast cancer with negative expression of estrogen receptor (ER), progesterone receptor (PR) and HER-2 / neu. It progresses rapidly, with a very poor prognosis, and the 5-year survival rate is less than 15%. TNBC is ineffective for hormone therapy and HER2 targeted therapy (such as Herceptin of Roche). Clinical treatment options are very limited and mainly rely on chemotherapy. Currently, there are 21 triple-negative breast cancer treatment drugs, 2 of which are on the market and 19 are in research. The first triple-negative breast cancer drug on the market was Roche's Atezolizumab, which was initially marketed in the United States in 2016. In 2019, global sales reached 1.932 billion US dollars. There are 4 types of triple-negative breast cancer drugs in clinical phase II, 5 types in clinical phase I / II, and 7 types in clinical phase I. It can be said that
  • 3. Biochempeg https://www.biochempeg.com the reserve power is sufficient, but the R & D progress is relatively slow. Drugs Targeting Trop2 At present, there are five drugs targeting Trop2 in the world. In addition to the listed Sacituzumab govitecan, the other four drugs under study are basically in clinical phase I. The fastest R & D progress is SKB-264 of Kelun Pharmaceutical, which is currently in the clinical I / II phase of solid tumor treatment. Related Articles: Anti-Cancer ADC Drugs: 3 Design Elements, 8 Approved ADCs, Multiple Clinical Trials ADC Drugs to be Launched In 2020 ADCs for Clinical Research in the Global Market History and Development of Antibody Drug Conjugates (ADCs) ADCs Against Cancer: Clinical Landscape and Challenges